D.E. Shaw & Co
PCVX icon

D.E. Shaw & Co’s Vaxcyte PCVX Stock Holding History

D.E. Shaw & Co’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$167M Sell
2,865,318
-765,735
-21% -$41.6M 0.1% 233
2025
Q4 		$168M Sell
3,631,053
-659,737
-15% -$29.5M 0.09% 241
2025
Q3 		$155M Buy
4,290,790
+1,202,340
+39% +$39.8M 0.09% 261
2025
Q2 		$100M Buy
3,088,450
+2,220,559
+256% +$72.8M 0.07% 330
2025
Q1 		$32.8M Buy
867,891
+92,238
+12% +$7.37M 0.03% 669
2024
Q4 		$63.5M Buy
775,653
+352,155
+83% +$35M 0.05% 470
2024
Q3 		$48.4M Buy
423,498
+193,291
+84% +$17.4M 0.04% 519
2024
Q2 		$17.4M Sell
230,207
-137,042
-37% -$9.33M 0.02% 968
2024
Q1 		$25.1M Sell
367,249
-71,062
-16% -$4.92M 0.02% 804
2023
Q4 		$27.5M Sell
438,311
-100,073
-19% -$5.2M 0.02% 749
2023
Q3 		$27.4M Sell
538,384
-274,528
-34% -$13.5M 0.03% 684
2023
Q2 		$40.6M Buy
812,912
+18,005
+2% +$853K 0.04% 511
2023
Q1 		$29.8M Sell
794,907
-177,414
-18% -$7.53M 0.03% 675
2022
Q4 		$46.6M Buy
+972,321
New +$38.2M 0.05% 458

Other funds holding PCVX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

D.E. Shaw & Co's PCVX Position: Q1 2026 in Review

D.E. Shaw & Co reduced its Vaxcyte (PCVX) stake by 21% in Q1 2026, selling an estimated $41.6M and leaving 2,865,318 shares worth $167M. The position accounts for 0.1% of the portfolio, ranked #233.

D.E. Shaw & Co first reported a position in PCVX in Q4 2022 and has held it in 14 quarters since. The position peaked at $168M in Q4 2025. 336 funds tracked by Wall St. Rank hold PCVX as of Q1 2026.

  • D.E. Shaw & Co held 2,865,318 shares of Vaxcyte worth $167M as of Q1 2026.
  • D.E. Shaw & Co sold 765,735 Vaxcyte shares in Q1 2026, an estimated $41.6M.
  • Vaxcyte made up 0.1% of D.E. Shaw & Co's portfolio in Q1 2026, its #233 holding.
  • D.E. Shaw & Co first reported a position in Vaxcyte in Q4 2022 and has held it in 14 quarters since.
  • D.E. Shaw & Co's Vaxcyte position peaked at $168M in Q4 2025.
  • 336 funds tracked by Wall St. Rank held Vaxcyte as of Q1 2026.

Based on D.E. Shaw & Co's 13F filing for Q1 2026, filed 15 May 2026.